SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-007190
Filing Date
2023-01-12
Accepted
2023-01-12 16:10:32
Documents
14
Period of Report
2023-01-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d447019d8k.htm   iXBRL 8-K 31973
2 EX-99.1 d447019dex991.htm EX-99.1 8084
6 GRAPHIC g447019g0112105939339.jpg GRAPHIC 5393
  Complete submission text file 0001193125-23-007190.txt   179495

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20230106.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20230106_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20230106_pre.xml EX-101.PRE 11714
8 EXTRACTED XBRL INSTANCE DOCUMENT d447019d8k_htm.xml XML 3459
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 23526035
SIC: 2834 Pharmaceutical Preparations